Growth axis
CJC-1295 with DAC
A GHRH 1-29 analogue carrying a drug-affinity-complex modification for longer persistence
£20.902mg
≥99% HPLCBatch testedIdentity by MS, purity by HPLC
Lot numberedCertificate filed per lot
Cold stored2 to 8 °C until dispatch
CJC-1295 without DAC
2mg lyophilised powderCAS 863288-34-0
A modified GHRH 1-29 analogue used to study GHRH receptor binding and growth-hormone axis feedback.
£12.95per vial, VAT included
In stock, dispatched same day before 16:00
- Free shipping on UK orders over £20.00
- Same day dispatch on orders placed before 16:00
- Batch certificate in the COA Database
Sold for research purposes only. For in-vitro laboratory research. Not a medicine and not for human or animal consumption. Supplied to qualified individuals aged 18 and over; you confirm this at checkout.
Research overview
CJC-1295 without DAC is a modified analogue of growth-hormone-releasing hormone, a 29-residue peptide with a D-alanine at position 2 and a C-terminal amide. It is studied in vitro and in preclinical models of GHRH receptor binding and growth-hormone axis feedback. Supplied at 2mg as a lyophilised powder for in-vitro laboratory research only.
Growth-hormone-releasing hormone acts through the GHRH receptor, a G protein-coupled receptor on pituitary somatotrophs that signals mainly through cAMP. The native hormone is cleaved quickly by dipeptidyl peptidase IV. The D-alanine at position 2 and the other changes in this modified sequence are described in the literature as improving resistance to that cleavage, so the peptide lasts longer in culture media while keeping receptor binding.
Typical work includes receptor-binding studies, cAMP assays in transfected cell lines and growth-hormone release assays in primary pituitary cultures. Researchers also compare its stability against native GHRH and against the DAC-bearing analogue, using HPLC or mass spectrometry to follow intact peptide over time. It is supplied as a lyophilised powder.
Research areas
- GHRH receptor binding in transfected cell lines
- cAMP signalling in pituitary cell models
- Growth-hormone release assays in culture
- Enzymatic stability against dipeptidyl peptidase IV
- Comparison with native GHRH and DAC analogues
Specifications
- CAS number
- 863288-34-0
- Molecular formula
- C152H252N44O42
- Molecular weight
- 3367.9 g/mol (approximate)
- Sequence
- Y-[D-Ala]-DAIFTQSYRKVLAQLSARKLLQDILSR-NH2 (Mod GRF 1-29; D-Ala at position 2; C-terminal amide)
- Form
- lyophilised powder
- Purity
- ≥99% (HPLC)
- Also known as
- CJC-1295, Modified GHRH (1-29) analogue, Tetrasubstituted GHRH (1-29), Growth Hormone-Releasing Hormone analogue.
- Supplied as
- 2mg per vial, lyophilised powder
Storage and handling
Store the lyophilised powder cold, dry and protected from light, and allow the vial to warm to room temperature before it is opened. Reconstitute with an appropriate laboratory diluent and keep any reconstituted material cold.
Certificates of analysis
Each lot of CJC-1295 without DAC is released with a certificate recording identity and purity. Enter the lot number printed on your vial on the lab testing page to view it.
Questions
How does CJC-1295 without DAC differ from the version with DAC?
The backbone is the same modified GRF 1-29 sequence, but this form carries no drug affinity complex. The DAC version adds a C-terminal lysine with a maleimide-based group reported to bind albumin and lengthen persistence.
What form does it come in and how should it be kept?
It is a lyophilised powder in a 2mg vial. Keep it cold, dry and away from light. Reconstitute only when the material is needed, using a suitable laboratory diluent.
Is CJC-1295 without DAC a medicine?
No. It is supplied strictly for in-vitro laboratory research. It is not a medicine, food or supplement, and it is not for human or animal use. Buyers must be aged 18 or over.
